Innovative cheese-making process lowers phosphorus and sodium content in chronic kidney disease patients, suggesting improved nutrition.
Patients with impaired renal function have several dietary limitations, including cheese for both its high phosphorusand sodium content. However, cheese is an important component of the European diet, and its limitation,together with the many other deprivations, negatively affects patients’ quality of life and nutrition. Wehave developed a cheese-making process characterized by the enrichment of milk with calcium carbonate toprovide patients with a nutritional opportunity while improving their phosphorus control. The procedure can beapplied to any type of milk and cheese. The derived products (identified by the designation of FriP) have optimalpalatability, being indistinguishable from regular cheese. FriP cheese has a very low concentration of absorbablephosphorus and a low sodium content. FriP cheese has proven its efficacy in lowering phosphorus absorption inboth healthy subjects and in chronic kidney disease (CKD) patients, as well as its safety as to calcium metabolism.Herein, we share the story of how FriP cheese has been developed to become an additional resource for overcomingsome of the dietary limitations of patients with CKD towards better nutrition, phosphorus control, andquality of life.
No takes yet. Share an insight, caveat, or question.
Mancuso et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: